Spots Global Cancer Trial Database for epoetin alfa
Every month we try and update this database with for epoetin alfa cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer | NCT00246597 | Anemia Breast Neoplasm... Hemoglobins Quality of Life Chemotherapy, A... | epoetin alfa | 18 Years - | Ortho Biotech Products, L.P. | |
| A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy. | NCT00350090 | Anemia Neoplasms | Epoetin Alfa | 18 Years - | Ortho Biotech Products, L.P. | |
| Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia | NCT00843882 | Anemia Chronic Myelomo... de Novo Myelody... Myelodysplastic... | Bone Marrow Bio... Epoetin Alfa Laboratory Biom... Lenalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer | NCT00004917 | Anemia Head and Neck C... | epoetin alfa cisplatin radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
| An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes | NCT01381809 | Myelodysplastic... | Group 2: Placeb... Group 1: Epoeti... | 18 Years - | Janssen-Cilag International NV | |
| Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer | NCT00014222 | Breast Cancer | epoetin alfa filgrastim cyclophosphamid... doxorubicin hyd... epirubicin hydr... fluorouracil paclitaxel | - 60 Years | Canadian Cancer Trials Group | |
| RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia | NCT00495378 | Chemotherapy Cancer Anemia | epoetin alfa | 18 Years - | Ortho Biotech Products, L.P. | |
| Survey on QUality of Life In myeloDisplasia (SQUID) | NCT00967564 | Myelodysplastic... | epidemiologic s... | 18 Years - | Janssen-Cilag S.p.A. | |
| Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy | NCT00052221 | Fatigue Unspecified Adu... | Epoetin alfa Placebo | 18 Years - | M.D. Anderson Cancer Center | |
| Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy | NCT01099202 | Leukemia | Procrit (epoeti... | - | M.D. Anderson Cancer Center | |
| A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy | NCT00216541 | Anemia Neoplasms | epoetin alfa | 18 Years - | Janssen-Cilag B.V. | |
| Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma | NCT00400686 | Anemia Multiple Myelom... Plasma Cell Neo... | epoetin alfa | 18 Years - | The Cleveland Clinic | |
| Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia | NCT00017004 | Anemia Cervical Adenoc... Cervical Adenos... Cervical Squamo... Drug Toxicity Radiation Toxic... Stage IIB Cervi... Stage III Cervi... Stage IVA Cervi... | External Beam R... Cisplatin Internal Radiat... Epoetin Alfa | - | GOG Foundation | |
| A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy. | NCT00350090 | Anemia Neoplasms | Epoetin Alfa | 18 Years - | Ortho Biotech Products, L.P. | |
| The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma | NCT00270101 | Anemia Multiple Myelom... | epoetin alfa | 40 Years - 80 Years | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer | NCT00246597 | Anemia Breast Neoplasm... Hemoglobins Quality of Life Chemotherapy, A... | epoetin alfa | 18 Years - | Ortho Biotech Products, L.P. | |
| Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy | NCT00083434 | Anemia Cancer | Epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia | NCT00017004 | Anemia Cervical Adenoc... Cervical Adenos... Cervical Squamo... Drug Toxicity Radiation Toxic... Stage IIB Cervi... Stage III Cervi... Stage IVA Cervi... | External Beam R... Cisplatin Internal Radiat... Epoetin Alfa | - | GOG Foundation | |
| Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy | NCT00270127 | Anemia Cancer Neoplasm | Epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy | NCT00388336 | Anemia Neoplasms | Epoetin Alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Effects of Exercise in Combination With Epoetin Alfa | NCT00577096 | Multiple Myelom... | Epoetin Alfa Exercise Autologous Peri... Red Blood Cell ... Thalidomide Heparin, Low-Mo... Platelet Transf... Melphalan Epoetin Alfa Total Therapy I... Red Blood Cell ... Thalidomide Heparin, Low-Mo... Platelet Transf... Melphalan | - | University of Arkansas | |
| A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS | NCT00656448 | Acute Myelogeno... Myelodysplastic... Leukemia | Procrit | - | M.D. Anderson Cancer Center | |
| A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) | NCT00446602 | Myelodysplastic... Anemia | Epoetin alfa | 18 Years - 99 Years | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy | NCT00003341 | Anemia Leukemia Lymphoma Multiple Myelom... | epoetin alfa quality-of-life... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy | NCT00216541 | Anemia Neoplasms | epoetin alfa | 18 Years - | Janssen-Cilag B.V. | |
| Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia | NCT01374373 | Antineoplastic ... | Epoetin alfa | 18 Years - | Bio Sidus SA | |
| Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia | NCT00017004 | Anemia Cervical Adenoc... Cervical Adenos... Cervical Squamo... Drug Toxicity Radiation Toxic... Stage IIB Cervi... Stage III Cervi... Stage IVA Cervi... | External Beam R... Cisplatin Internal Radiat... Epoetin Alfa | - | GOG Foundation | |
| A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer | NCT00269984 | Anemia | Epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer | NCT00028938 | Lung Cancer | epoetin alfa carboplatin paclitaxel radiation thera... | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma | NCT00270101 | Anemia Multiple Myelom... | epoetin alfa | 40 Years - 80 Years | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| The Duration Study | NCT00210730 | Anemia | epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy | NCT00306267 | Anemia Cancer Epoetin Alfa | epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma | NCT00400686 | Anemia Multiple Myelom... Plasma Cell Neo... | epoetin alfa | 18 Years - | The Cleveland Clinic | |
| Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia | NCT00481624 | Anemia | Epoetin Alfa pl... | 18 Years - | University of Louisville | |
| An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks | NCT00337948 | Chemotherapy Anemia Cancer | Epoetin alfa | 19 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer | NCT00060398 | Anemia Fatigue Prostate Cancer | epoetin alfa dexamethasone | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy | NCT00388336 | Anemia Neoplasms | Epoetin Alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer | NCT00049348 | Pancreatic Canc... | epoetin alfa filgrastim cisplatin fluorouracil gemcitabine hyd... adjuvant therap... conventional su... neoadjuvant the... radiation thera... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy | NCT00270166 | Anemia Multiple Myelom... Lymphoma Breast Cancer Ovarian Cancer Carcinoma, Smal... Esophagus Cance... Prostate Cancer Neoplasm | epoetin alfa | 18 Years - 80 Years | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy | NCT00270127 | Anemia Cancer Neoplasm | Epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma | NCT00270101 | Anemia Multiple Myelom... | epoetin alfa | 40 Years - 80 Years | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer | NCT00014222 | Breast Cancer | epoetin alfa filgrastim cyclophosphamid... doxorubicin hyd... epirubicin hydr... fluorouracil paclitaxel | - 60 Years | Canadian Cancer Trials Group | |
| Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer | NCT00028938 | Lung Cancer | epoetin alfa carboplatin paclitaxel radiation thera... | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer | NCT00014222 | Breast Cancer | epoetin alfa filgrastim cyclophosphamid... doxorubicin hyd... epirubicin hydr... fluorouracil paclitaxel | - 60 Years | Canadian Cancer Trials Group | |
| A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy | NCT00261677 | Anemia Hodgkin Disease Leukemia Lymphoma, Non-h... | epoetin alfa | 5 Years - 18 Years | Ortho Biotech Products, L.P. | |
| Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer | NCT00004917 | Anemia Head and Neck C... | epoetin alfa cisplatin radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
| An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy. | NCT00210834 | Anemia | epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy | NCT00266617 | Anemia Neoplasms | epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve | NCT03682536 | Myelodysplastic... | Luspatercept Epoetin alfa | 18 Years - | Celgene | |
| A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy | NCT00283465 | Anemia Neoplasm | Epoetin alfa | 18 Years - | Janssen-Cilag B.V. | |
| Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome | NCT00003681 | Anemia Myelodysplastic... | epoetin alfa amifostine trih... | 18 Years - | National Cancer Institute (NCI) | |
| An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy. | NCT00210834 | Anemia | epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia | NCT00017004 | Anemia Cervical Adenoc... Cervical Adenos... Cervical Squamo... Drug Toxicity Radiation Toxic... Stage IIB Cervi... Stage III Cervi... Stage IVA Cervi... | External Beam R... Cisplatin Internal Radiat... Epoetin Alfa | - | GOG Foundation | |
| Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia | NCT00264108 | Anemia Neoplasms | Darbepoetin alf... Epoetin alfa | 18 Years - | Janssen-Cilag B.V. | |
| Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia | NCT00338299 | Anemia Chemotherapy | Epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Dosing and Outcomes Study of Erythropoietic Stimulating Therapies in Patients With Chemotherapy Induced Anemia | NCT00212862 | Anemia Cancer | Patients with c... | 18 Years - | Ortho Biotech Products, L.P. | |
| Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy | NCT00524407 | Chemotherapy Anemia Cancer | Epoetin alfa | 18 Years - | Ortho Biotech Clinical Affairs, L.L.C. | |
| A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients | NCT00254436 | Gastrointestina... Rectal Cancer | Procrit (epoeti... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery | NCT00036400 | Stomach Neoplas... Rectal Neoplasm... | epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2) | NCT00398749 | Anemia Neoplasms | Epoetin alfa | 18 Years - | Janssen-Cilag B.V. | |
| A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve | NCT03682536 | Myelodysplastic... | Luspatercept Epoetin alfa | 18 Years - | Celgene | |
| Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia | NCT00264108 | Anemia Neoplasms | Darbepoetin alf... Epoetin alfa | 18 Years - | Janssen-Cilag B.V. | |
| Epoetin Alfa in Treating Anemia in Patients With Solid Tumors | NCT00058331 | Anemia Leukemia Lymphoma Lymphoprolifera... Multiple Myelom... Precancerous Co... Unspecified Adu... | epoetin alfa | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia | NCT00270049 | Anemia Leukemia, Lymph... Leukemia, Lymph... Cancer Neoplasms Quality of Life | epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia | NCT00315484 | Anemia Chemotherapy | Epoetin alfa an... | 18 Years - | Ortho Biotech Products, L.P. | |
| A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy | NCT00306267 | Anemia Cancer Epoetin Alfa | epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer | NCT00028938 | Lung Cancer | epoetin alfa carboplatin paclitaxel radiation thera... | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) | NCT01034657 | Myelodysplastic... | LBH589 Epoetin Alfa | 18 Years - | Novartis | |
| A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy | NCT00386152 | Neoplasms Anemia Cancer | epoetin alfa darbepoetin alf... | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy | NCT00266617 | Anemia Neoplasms | epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug | NCT00269997 | Anemia Neoplasms | epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20) | NCT00310232 | Non-Small-Cell ... Lung Cancer Anemia | Epoetin Alfa | 18 Years - | Ontario Clinical Oncology Group (OCOG) | |
| A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients | NCT00254436 | Gastrointestina... Rectal Cancer | Procrit (epoeti... | 18 Years - | M.D. Anderson Cancer Center | |
| An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks | NCT00338416 | Cancer Anemia | Epoetin alfa | 19 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2) | NCT00398749 | Anemia Neoplasms | Epoetin alfa | 18 Years - | Janssen-Cilag B.V. | |
| Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer | NCT00017277 | Head and Neck C... | epoetin alfa radiation thera... | 18 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy | NCT00003600 | Anemia Breast Cancer Chronic Myelopr... Drug/Agent Toxi... Leukemia Lung Cancer Lymphoma Multiple Myelom... Precancerous Co... Small Intestine... Unspecified Adu... | epoetin alfa placebo | 18 Years - | Alliance for Clinical Trials in Oncology | |
| An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation | NCT00210587 | Anemia Neoplasms | epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy | NCT00083434 | Anemia Cancer | Epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome | NCT00003681 | Anemia Myelodysplastic... | epoetin alfa amifostine trih... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
